KR20230149568A - Composition for preventing, improving or treating allergic respiratory disease comprising Alpinia officinarum extract as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, improving, or treating allergic respiratory diseases containing an extract of Goryang River as an active ingredient. Specifically, Goryanggang extract reduces airway hyperresponsiveness, inhibits the infiltration of immune cells such as eosinophils and neutrophils in nasal washing fluid increased by asthma induction, reduces IgE content in serum, and selectively induces Th2 immune responses. Because it has an excellent inhibitory effect, it can be usefully used in health functional foods and medicines for allergic respiratory diseases.

Description

Composition for preventing, improving or treating allergic respiratory disease comprising Alpinia officinarum extract as effective component}

The present invention relates to a composition for preventing, improving, or treating allergic respiratory diseases containing an extract of Goryang River as an active ingredient.

The incidence of allergic diseases is increasing significantly around the world, and in particular, in the case of asthma, which accounts for 80% of allergic diseases, there is a correlation between the incidence and mortality, so investment in preventive drug treatment and research to suppress progression is urgently needed. In particular, among allergic diseases, asthma is a hypersensitivity reaction of the bronchial tubes to various irritants that enter during breathing, causing inflammation and swelling of the airway mucosa, including the bronchial tubes, and narrowing of the bronchial tubes, resulting in coughing accompanied by wheezing (wheezing breathing sounds). , a disease in which sputum production and shortness of breath appear in fits and starts, and various immune cells, especially mast cells, neutrophils, and basophils, are present in excess in the airways of patients with asthma. These immune cells react sensitively to external irritants that have no effect on normal people and promote excessive action, resulting in symptoms of epithelial cell damage, mucus and secretion, vasodilatation, and airway remodeling. Factors causing asthma can be broadly divided into genetic factors and environmental factors. Genetic factors may include airway hyperresponsiveness, gender, and race, while environmental factors may include house dust, mites, air pollution, smoking, and diet.

Bronchial asthma treatments are broadly divided into controllers and symptom relievers. Controllers such as inhaled glucocorticosteroids, anti-allergic drugs, and long-acting bronchodilators are used to prevent worsening of asthma in the long term. Symptom relievers use bronchodilators, which are used to urgently relieve symptoms such as acute asthma attacks or bronchial infarction. In any case, there is no major problem in relieving the symptoms of mild asthma disease, but there are significant problems in treating mid- or late-stage asthma, and the problem of serious side effects or inconvenience when using high doses of inhaled steroid drugs is emerging. there is. Due to the nature of asthma disease, long-term drug use is inevitable, but conventional asthma treatments such as steroids and smooth muscle relaxants have many side effects such as decreased immunity, infection, and effects on the heart, so the side effects of the drugs are almost nonexistent, and the fundamental disease condition can be improved or treated. As the development of new effective drugs is urgently needed, there is a need for asthma treatments that can reduce or eliminate the side effects of conventional drugs.

Meanwhile, Alpinia officinarum Hance is a perennial herb belonging to the ginger family. The rhizome is dug up in the fall and dried. In eastern medicine, it is said to be effective in treating abdominal pain, vomiting, and diarrhea, as well as poor kidney function, loss of stamina due to sensitivity to cold, and dysentery. It is known that its main pharmacological actions include promoting gastric juice secretion, analgesic action, anti-oxidation effect, anti-thrombotic action, anti-coagulant action, and improvement of peripheral circulation.

Prior art related to allergic respiratory diseases includes 'Composition for preventing or treating allergic respiratory diseases containing sea cucumber extract as an active ingredient' in Korean Patent No. 1808615, and Korean Patent Publication No. 2017-0000491. 'A composition for preventing allergic rhinitis and treating nasal congestion comprising cabbage extract, elm extract, Noria tree extract, and Acanthopanax extract as active ingredients' is disclosed. However, the present invention's 'composition for preventing, improving, or treating allergic respiratory diseases containing Goryanggang extract as an active ingredient' has not yet been disclosed.

The present invention was developed in response to the above-mentioned needs, and the present invention provides a composition for preventing, improving, or treating allergic respiratory diseases containing the Koryanggang extract as an active ingredient, and the Goryanggang extract reduces airway hyperresponsiveness. The present invention was completed by confirming that it suppresses the infiltration of immune cells such as eosinophils and neutrophils in the nasal washing fluid increased by asthma induction, reduces the IgE content in the serum, and selectively suppresses the Th2 immune response.

In order to solve the above problems, the present invention provides a health functional food composition for preventing or improving allergic respiratory diseases containing Goryangkang extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating allergic respiratory diseases containing an extract of Goryang River as an active ingredient.

In addition, the present invention provides a quasi-drug for preventing or improving allergic respiratory diseases containing Goryangkang extract as an active ingredient.

In addition, the present invention provides a feed additive for preventing or improving allergic respiratory diseases containing Goryang River extract as an active ingredient.

The present invention relates to a composition for preventing, improving or treating allergic respiratory diseases containing Goryanggang extract as an active ingredient. The Goryanggang extract reduces airway hyperresponsiveness, eosinophils and It has the effect of suppressing the infiltration of immune cells such as neutrophils, reducing the IgE content in the serum, and selectively suppressing the Th2 immune response.

Figure 1 is a schematic diagram of an animal test method confirming the improvement effect of allergic asthma by administering the Goryanggang extract of the present invention in an animal model in which allergic asthma was induced through ovalbumin (OVA) treatment.
Figure 2 shows airway resistance (Rrs, resistance) (A), middle airway resistance (Rn, Newtonian resistance) (B) and elasticity (Ers, elastance) according to administration of the Koryanggang extract of the present invention in an allergic asthma-induced animal model. )(C) This is the result of checking the degree. NC is the normal group, OVA is the allergic asthma induction group treated with Ovalbumin (OVA), and DEX is the positive control group treated with Dexamethasone. #### indicates a statistically significant increase in airway resistance, middle airway resistance, and elasticity in the allergic asthma-induced group compared to the normal group, p<0.0001. **** shows a statistically significant decrease in airway resistance, middle airway resistance, and elasticity in the group administered Goryanggang extract at all concentrations and the group administered dexamethasone (DEX, Dexamethasone), which is a positive control group, compared to the allergic asthma inducer group (OVA). That is, p<0.0001.
Figure 3 shows the numbers of eosinophils (A), neutrophils (B), and total cells (C) in bronchoalveolar lavage fluid according to administration of the Koryanggang extract of the present invention in an allergic asthma-induced animal model. This is the result of confirming the reduced effect. NC is the normal group, OVA is the allergic asthma-induced group treated with ovalbumin (OVA), JW2L and JW2H are the groups administered 100 mg/kg and 300 mg/kg of Goryanggang extract, and DEX is the positive control group, dexamethasone ( Dexamethasone) administration group. ### indicates a statistically significant increase in the number of eosinophils, neutrophils, and total cells in the allergic asthma-induced group compared to the normal group, p<0.001. *, **, and *** represent the numbers of eosinophils, neutrophils, and total cells in the bronchoalveolar lavage fluid of the Goryanggang extract-administered group (JW2L or JW2H) or the positive control group, dexamethasone-administered group (DEX, Dexamethasone) compared to the allergic asthma inducer group (OVA). Statistically significant decrease means * means p<0.05, ** means p<0.01, and *** means p<0.001.
Figure 4 shows the results confirming the effect of reducing the total IgE level in the serum following administration of the Goryanggang extract of the present invention in an allergic asthma-induced animal model. NC is the normal group, OVA is the allergic asthma-induced group treated with ovalbumin (OVA), JW2L and JW2H are the groups administered 100 mg/kg and 300 mg/kg of Goryanggang extract, and DEX is the positive control group, dexamethasone ( Dexamethasone) administration group. ### indicates a statistically significant increase in the total IgE level in the serum of the allergic asthma induced group compared to the normal group, p<0.001. * and *** indicate a statistically significant decrease in total serum IgE levels in the group administered 300 mg/kg of Goryanggang extract (JW2H) and the group administered dexamethasone (DEX, Dexamethasone), a positive control group, compared to the allergic asthma induction group (OVA). * means p<0.05, and *** means p<0.001.
Figure 5 shows the results of confirming changes in Th1 cytokine (IL-2) and Th2 cytokine (IL-4) content and cell survival rate in spleen cells isolated from an allergic asthma-induced animal model upon administration of the Goryanggang extract of the present invention. am. ConA(-) is a normal group that was not treated with concanavalin A, and ConA(+) is a group that was treated with concanavalin A to induce cytokine production. ### indicates a statistically significant increase in IL-2 and IL-4 contents in spleen cells of the cytokine production induced group compared to the normal group, p<0.001. * and *** indicate a statistically significant decrease in IL-4 content in spleen cells of the Goryang River extract administration group (30, 100㎍/㎖) compared to the cytokine production induced group, * is p < 0.05, and ** * means p<0.001.

In order to achieve the object of the present invention, the present invention provides a health functional food composition for preventing or improving allergic respiratory diseases containing Goryangkang extract as an active ingredient.

The allergic respiratory disease may preferably be allergic asthma or allergic rhinitis, and more preferably allergic asthma, but is not limited thereto.

The Goryang River extract can be prepared by a method including the following steps, but is not limited to this:

(1) Extracting by adding an extraction solvent to Goryang River;

(2) filtering the extract of step (1); and

(3) Concentrating and drying the filtered extract of step (2) to prepare an extract.

In step (1), the extraction solvent is preferably selected from water, lower alcohols of C ₁ to C ₄ , or mixtures thereof, more preferably water, but is not limited thereto.

In the above manufacturing method, the extraction method can be any conventional method known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The extraction solvent is preferably added at 1 to 20 times the weight of Goryang River for extraction, and more preferably at 5 to 15 times. The extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but is not limited to this. In the above method, the vacuum concentration in step (3) is preferably performed using a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, drying is preferably performed by reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

The composition is preferably manufactured in a dosage form selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When using the health functional food composition of the present invention as a food additive, the Koryanggang extract can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention or improvement). Generally, when producing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no special restrictions on the types of foods above. Examples of foods to which the extract can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, These include alcoholic beverages and vitamin complexes, and include all health functional foods in the conventional sense.

When the composition of the present invention is used as a health drink, it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional drinks. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as textrin and cyclotenstrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumarin and stevia extract or synthetic sweeteners such as saccharin or aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal neutralizer, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonic acid. It may contain carbonating agents used in beverages. Additionally, the composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

In addition, the present invention provides a pharmaceutical composition for preventing or treating allergic respiratory diseases containing an extract of Goryang River as an active ingredient.

The composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents in addition to the above active ingredients, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc. These solid preparations contain one or more compounds and at least one excipient, such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, aerosols, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspension solvents may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycero gelatin, etc. can be used. When administering parenterally, it is preferable to choose external application through the skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dura, or intracerebrovascular injection.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount is determined by the type, severity, and activity of the patient's disease. , can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The dosage of the composition of the present invention varies depending on the patient's weight, age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of disease. The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and methods using biological response modifiers.

In addition, the present invention provides a quasi-drug for preventing or improving allergic respiratory diseases containing Goryangkang extract as an active ingredient.

The term "quasi-drug" used in the present invention refers to products with a milder effect than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases in humans or animals. For example, according to the Pharmaceutical Affairs Act. According to it, quasi-drugs exclude products used for medicinal purposes, and include products used to treat or prevent diseases in humans and animals, or products that have a mild or no direct effect on the human body.

The quasi-drug of the present invention is used for the purpose of improving allergic diseases, and there is no particular limitation in its formulation, and in each formulation, the quasi-drug can arbitrarily select and mix other ingredients according to the formulation or purpose of use of the other quasi-drug. You can. The amount of active ingredients mixed can be appropriately determined depending on the purpose of use (suppression or alleviation). For example, it may include conventional auxiliaries such as thickeners, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.

In addition, the present invention provides a feed additive for preventing or improving allergic respiratory diseases containing Goryang River extract as an active ingredient.

The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.

Hereinafter, the present invention will be described in detail through examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.

[Materials and Methods]

1. Experimental animals

Female 7-week-old SPF Balb/c mice (20 g) were supplied by Central Laboratory Animal Company (Japan SLC Inc.). Animals were provided with sufficient solid feed (no antibiotics, Samyang Feed Co.) and water until the day of the experiment, and were acclimatized for one week in an environment with a temperature of 22 ± 2°C, humidity of 55 ± 15%, and 12 hours (light-dark cycle). It was used in the experiment.

2. Asthma model and sample administration

After a one-week acclimatization period, mice were sensitized by intraperitoneal injection of 200 μl of PBS containing 2 mg of aluminum hydroxide (Sigma-Aldrich) and 50 μg of ovalbumin (OVA; ovoalbumin, Sigma-Aldrich) suspended at weekly intervals. I ordered it. The Goryanggang extract (100mg/kg and 300mg/kg) of the present invention and dexamethasone (1mg/kg), a positive control group, were administered orally daily from the 11th to the 17th, and the respiratory anesthetic isoflu was administered from the 14th to the 17th. After inhalation anesthesia with isoflurane (Piramal critical care Inc), 25 μg/mice (50 μl) of OVA was administered intranasally. Airway hyperresponsiveness (AHR) was measured within 24 hours after the last intranasal administration, and blood was collected after anesthesia by intraperitoneal administration of pentobarbital (Entobar inj, Hallym Pharmaceuticals), and a bronchial incision was performed. After inserting a catheter into the affected area, a 1 ml syringe was connected to inject 0.5 ml of PBS into the lungs and then collected. This was repeated a total of 2 times to collect 1 ml of bronchoalveolar lavage fluid.

3. Measurement of airway resistance (Rrs, Resistance), elasticity (Ers, elastance) and middle airway resistance (Rn, Newtonian resistance)

To measure airway hyperresponsiveness due to asthma, FlexiVent (SCIREQ, Canada) was used. Airway resistance, elasticity, and mid-airway resistance were measured using methylcholine (Sigma-Aldrich). Methylcholine was inhaled at gradually increasing concentrations of 0, 6.25, 12.5, 25, and 50 mg/ml and then inhaled for 3 days. Minutes were measured.

4. Bronchoalveolar lavage fluid (BALF) separation and inflammatory cell count measurement

The total number of cells in each bronchoalveolar lavage fluid (BALF) was measured using a hemocytometer. To identify inflammatory cells, cells in the bronchoalveolar lavage fluid were attached to a slide using Cytospin (Hanil), then Diff-Quik staining (Sysmex) was performed and eosinophils and other inflammatory cells were examined under a microscope. Afterwards, inflammatory cells were measured by taking microscopic photographs at 200x magnification. The ratio of identified inflammatory cells was applied to the total number of cells to differentially count inflammatory cells in bronchoalveolar lavage fluid.

5. Serum analysis

Blood obtained through the posterior vena cava was reacted at room temperature for 30 minutes and then centrifuged (3000 rpm, 15 minutes) to obtain serum. Total IgE concentration was measured using an ELISA kit (Biolegend, USA).

6. Measurement of Th1/Th2 cytokines in splenocytes

Animal experiments to isolate cells from mouse spleens were performed after receiving approval from the IACUC of the Korea Institute of Oriental Medicine (approval number: 20-022, March 23, 2020). BALB/c mice (5 weeks old, male) were purchased from SLC, Japan through Central Laboratory Animals. After stabilization in an SPF facility for one week, the mice were sacrificed and spleen tissue was removed. Cells were separated from spleen tissue using a 40 μM cell strainer (Falcon), and then red blood cells were lysed using RBC lysis buffer (Biolegend). Spleen isolated after preparing RPMI1640 medium (Gibco) supplemented with 10% FBS (Fetal Bovine Serum; Gibco, Thermo Fisher Scientific) and 1% antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin; Gibco) Cells were dispensed into 96-well culture plates at 5×10 ⁶ cells/ml. Splenocytes were treated with Baekduong extract (3, 10, 30, 100㎍/㎖) and 2.5㎍/㎖ concanavalin A (Sigma Aldrich) and cultured for 24 hours. Afterwards, the cell culture medium was obtained and used to measure cytokines, and the cell viability of the cells was measured using the EZ-Cytox cell viability assay kit (Daeil Lab Service). Th1/Th2 cytokine expression levels were measured in the obtained cell culture using the LEGENDplex ^TM MU Th cytokine panel (Biolegend, Cat No. 741044) according to the manufacturer's instructions.

7. Statistical processing

All results were calculated as mean ± standard deviation (SD), and comparison between each experimental group was performed by one-way ANOVA using GraphPad software, and Duncan's multiple comparison test was performed as a post hoc test. ) was used to verify the significance between each group. If the p value was less than 0.05, it was determined that there was a statistically significant difference.

Example 1. Preparation of Goryang River extract

Add 1kg of dried Alpinia officinarum to 10L of distilled water, extract under reflux (heating mantle) at 100±2°C for 3 hours, filter through a strainer, and secondly filter with a test sieve (Test Sieve 53㎛ No. 270). A hot water extract was obtained and freeze-dried. In animal experiments, the freeze-dried extract was dissolved in sterilized purified water and used. In the cell experiment, Goryang River thermal water extract dissolved in distilled water was filtered through a 0.22㎕ filter and then used in the experiment.

Example 2. Confirmation of changes in airway hyperresponsiveness following administration of Goryangkang extract

To confirm airway hyperresponsiveness (AHR) due to methacholine induction, the degrees of airway resistance (Rrs), elasticity (Ers), and middle airway resistance (Rn, Newtonian resistance) were checked.

As a result, as shown in Figure 2, in the case of the asthma induction group (OVA), airway hyperresponsiveness increased in a concentration-dependent manner as methylcholine was treated at different concentrations (6.25, 12.5, 25, and 50 mg/ml). It was confirmed that asthma was induced. In contrast, in the experimental group administered Goryanggang extract (100 and 300 mg/kg/day) at different concentrations, the airway resistance (Rrs, resistance), elasticity (Ers, elastance), and middle airway resistance (Rn, Newtonian resistance) values It was confirmed that this significantly decreased in a concentration-dependent manner.

Example 3. Allergy A decrease in the number of inflammatory cells in bronchoalveolar lavage fluid was confirmed in an animal model with induced asthma.

Eosinophils, neutrophils, and total cells were confirmed in the bronchoalveolar lavage fluid of an allergic asthma animal model administered Goryanggang extract.

As a result, as shown in Figure 3, in the bronchoalveolar lavage fluid in the asthma-induced group (OVA) compared to the normal group (NC), The number of eosinophils, neutrophils, and total cells increased significantly, and in contrast, a statistically significant decrease was confirmed in the groups administered the Goryang River extract of the present invention (JW2L and J22H).

Example 4. Allergy Confirmation of total IgE content in serum in animal model with induced asthma

The total IgE level in the serum of an animal model in which allergic asthma was induced by administration of the Goryanggang extract of the present invention was confirmed. As a result, as shown in Figure 4, the total IgE concentration increased in the asthma-induced group (OVA) compared to the normal group (NC), and in contrast, the total IgE concentration in the high-concentration Goryanggang extract administration group (J2WH) of the present invention increased. decreased statistically significantly.

Example 5. Allergy Confirmation of changes in Th1 and Th2 cytokine content in spleen cells following administration of Goryanggang extract in an asthma-induced animal model

After administering Goryanggang extract to spleen cells isolated from an animal model in which allergic asthma was induced, Th1 and Th2 cytokine contents were measured.

As a result, as shown in Figure 5, the Th1 and Th2 cytokine content increased through treatment of mouse spleen cells with concanavalin A. In contrast, when the Goryanggang extract of the present invention was administered, Th1 It was confirmed that it did not affect the increase in cytokine IL-2 and cell survival rate, and selectively suppressed the increase in IL-4, a Th2 cytokine.

Claims (8)

A health functional food composition for preventing or improving allergic respiratory diseases containing Goryangkang extract as an active ingredient. The health functional food composition for preventing or improving allergic respiratory diseases according to claim 1, wherein the allergic respiratory disease is allergic asthma or allergic rhinitis. The health functional food composition for preventing or improving allergic respiratory disease according to claim 1, wherein the extraction solvent of the Goryang River extract is water, a lower alcohol of C ₁ to C ₄ , or a mixture thereof. The health functional food composition for preventing or improving allergic respiratory disease according to claim 1, wherein the composition is manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage. . A pharmaceutical composition for preventing or treating allergic respiratory diseases comprising an extract of Goryang River as an active ingredient. The pharmaceutical composition for preventing or treating allergic respiratory diseases according to claim 5, further comprising a pharmaceutically acceptable carrier, excipient, or diluent in addition to the active ingredient. A quasi-drug for preventing or improving allergic respiratory diseases containing Goryanggang extract as an active ingredient. A feed additive for preventing or improving allergic respiratory diseases containing Goryang River extract as an active ingredient.